TGV

TGV-Laboratories is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for infectious diseases and oncology. The company utilizes its proprietary TGV-Discovery platform to design small molecules that target specific viral and cancer-related pathways. Its lead candidate, TGV-28, is a broad-spectrum antiviral agent that has been evaluated in clinical trials for the treatment of COVID-19 and other respiratory viruses. Additionally, TGV-Laboratories is advancing a pipeline of immunomodulators aimed at treating various solid tumors and chronic viral infections like HIV. The company's research is heavily focused on the intersection of microbiology and human health, particularly the role of the microbiome in disease progression.